Top

Archives of Gynecology and Obstetrics

Published in:

01-04-2012 | General Gynecology

Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion

Authors: Krishna Dahiya, Kamlesh Ahuja, Atul Dhingra, Nirmala Duhan, Smiti Nanda

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Abstract

Objectives

To evaluate the efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone in medical abortion of ≤56 days.

Study design

One hundred pregnant women having gestational age ≤56 days were randomized to group A and group B. In group A, patients received 200 mg mifepristone on day 1, followed by buccal misoprostol 800 µg on day 2, and in group B patients received 800 µg buccal misoprostol only on day 1.

Main outcome measures

Complete abortion was the principal outcome measure. Secondary outcome measures were side-effects and acceptability.

Results

Forty-six (92%) patients in group A and 37 (74%) patients in group B aborted successfully (p value 0.017). Four (8%) patients in group A and eight (16%) patients in group B had incomplete abortion with retained products of conception. In group B, three (6%) patients had missed abortion and two (4%) patients had continued pregnancy whereas none of the patients in group A had missed abortion or continued pregnancy. The overall method acceptance was 100% whereas the overall route acceptance was 83%.

Conclusion

Misoprostol-alone regimen is a low-cost regimen as compared to mifepristone/misoprostol regimen. Though the efficacy of mifepristone followed by buccal misoprostol is better, buccal misoprostol alone can be used for termination of pregnancy in patients where mifepristone is either unavailable or contraindicated.

Clark W, Gold M, Grossman D, Winnikoff B (2007) Can mifepristone medical abortion be simplified? Contracept 75:245–250CrossRef

Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E et al (2005) Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contracept 72:328–332CrossRef

Castleman LD, Oanh KT, Hyman AG, Thuy Le T, Blumenthal BD (2006) Introduction of the dilatation and evacuation procedure for second trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. Contracept 74:272–276CrossRef

Carlan SJ, Blust D, O’Brien W (2002) Buccal versus intravaginal misoprostol administration for cervical ripening. Obstet Gynecol 186:229–233CrossRef

Elul B, Hajri S, Ngoc NN, Ellertson C, Slama CB, Pearlman E et al (2001) Can women in less developed countries use a simplified abortion regimen? Lancet 357:1402–1405PubMedCrossRef

UK Multicentre Trial (1990) The efficacy, tolerance of mifepristone, prostaglandin in first trimester termination of pregnancy. Br J Obstet Gynecol 97:480–486CrossRef

World Health Organization (1993) Termination of pregnancy with reduced doses of mifepristone. Br Med J 307:532–537CrossRef

Baird DT, Sukcharoen N, Thong KJ (1995) Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum Reprod 10:1521–1527PubMed

Heikinheimo O, Croxatto H, Salvatierra AM, Chang CC, Luukkainen T, Lahteemaki P (1987) Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans. Hum Reprod 2:645–648PubMed

10.

Brogden RN, Goa KL, Faylds D (1993) Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 45:384–409PubMedCrossRef

11.

Heikinheimo O (1989) Pharmacokinetics of antiprogesterone (RU 486) in women during multiple doses administration. J Steroid Biochem 32(Suppl lA):21–25PubMedCrossRef

12.

Winikoff B, Dzuba IG, Creinin MD, Mitchell DC, Crowden WA (2008) Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 112:1303–1310PubMedCrossRef

13.

Fjerstad M, Sivin I, Lichtenberg ES, Trussell J, Cleland K, Cullins V (2009) Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days. Contracept 80(3):282–286CrossRef

14.

Bugalho A, Mocumbi S, Faúndes A, David E (2000) Termination of pregnancies of <6 weeks gestation with a single dose of 800 μg of vaginal misoprostol. Contracept 61:47–50CrossRef

15.

Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr (2002) A prospective randomized, double blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 17(6):1477–1482PubMedCrossRef

16.

Lohr PA, Matthew FR, Jennifer LH, Bryna H, Mitchell DC (2007) Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. Contracept 76:215–220CrossRef

Title: Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion
Authors: Krishna Dahiya
Kamlesh Ahuja
Atul Dhingra
Nirmala Duhan
Smiti Nanda
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-011-2110-8

At a glance: The STEP trials

Springer Medicine

Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion

Abstract

Objectives

Study design

Main outcome measures

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Study design

Main outcome measures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Co-expression of bone morphogenetic protein 6 with estrogen receptor a in endometriosis

Assessment of β-human chorionic gonadotropin level as a reliable predictor of tubal patency confirmed with transvaginal ultrasound-guided selective salpingography (TVSSG) following conservative treatment of tubal pregnancy

Influence of pregnancy on bone density: a risk factor for osteoporosis? Measurements of the calcaneus by ultrasonometry

Retrospective analysis of the efficacy of perioperative use of the cell salvage and autologous blood recovery system during laparoscopic myomectomy

Coenzyme Q10 content in follicular fluid and its relationship with oocyte fertilization and embryo grading

Efficacy of transcutaneous electrical nerve stimulation for pain relief in women undergoing office endometrial biopsy